About CytoDyn

CytoDyn is committed to enhancing the lives of men and women with HIV. We focus on developing new therapies that provide flexibility and freedom to people across the globe who are living with HIV. 

Read More About CytoDyn

Leronlimab (PRO 140)

Our lead product, PRO 140, belongs to a new class of HIV/AIDS therapeutics that protects healthy cells from viral infection.  PRO 140 has several potential benefits including less frequent dosing and minimal side effects that distinguish it from currently used HIV treatments.

Read More About Leronlimab (PRO 140)

CCR5 and Cancer

Our CMO Dr. Richard Pestell, MD, PhD, MB, BS, FACP, FRACP, FAAAS, MBA, is a world renowned oncologist and researcher. Dr. Pestell has played an instrumental role in identifying the role of CCR5 in cancer indications, and has worked to develop CCR5 technology

Is good health a choice?: Richard Pestell at TEDxOccidentalCollege

Learn About CCR5 & Dr. Pestell's Research
Watch how leronlimab (PRO 140) combats HIV
Watch how leronlimab (PRO 140) combats HIV
View Video
CytoDyn’s Expanded Strategic Direction
CytoDyn’s Expanded Strategic Direction

As described by Nader Pourhassan, Ph.D., President & CEO, and Richard Pestell, M.D., Ph.D., Chief Medical Officer

View Video